Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights
Viruses · 12.03.2024 · 16 (3) · 442
DOI: 10.3390/v16030442 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 12.03.2024. Verfasst von Estrella Lopez-Gordo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Affinia Therapeutics, Waltham, MA 02453, USA. Hauptthemen laut MEDLINE: Capsid, Dependovirus. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 376 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Today, adeno-associated virus (AAV)-based vectors are arguably the most promising in vivo gene delivery vehicles for durable therapeutic gene expression. Advances in molecular engineering, high-throughput screening platforms, and computational techniques have resulted in a toolbox of capsid variants with enhanced performance over parental serotypes. Despite their considerable promise and emerging clinical success, there are still obstacles hindering their broader use, including limited transduction capabilities, tissue/cell type-specific tropism and penetration into tissues through anatomical barriers, off-target tissue biodistribution, intracellular degradation, immune recognition, and a lack of translatability from preclinical models to clinical settings. Here, we first describe the transduction mechanisms of natural AAV serotypes and explore the current understanding of the systemic and cellular hurdles to efficient transduction. We then outline progress in developing designer AAV capsid variants, highlighting the seminal discoveries of variants which can transduce the central nervous system upon systemic administration, and, to a lesser extent, discuss the targeting of the peripheral nervous system, eye, ear, lung, liver, heart, and skeletal muscle, emphasizing their tissue and cell specificity and translational promise. In particular, we dive deeper into the molecular mechanisms behind their enhanced properties, with a focus on their engagement with host cell receptors previously inaccessible to natural AAV serotypes. Finally, we summarize the main findings of our review and discuss future directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affinia Therapeutics, Waltham, MA 02453, USA.
- Independent Researcher, South Plainfield, NJ 07080, USA.
- Spark Therapeutics, Philadelphia, PA 19104, USA.
ORCID-Profile: Estrella Lopez-Gordo, Thomas Weber
Zitieren
APA
Lopez-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024). Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights. Viruses, 16(3), 442. https://doi.org/10.3390/v16030442
Vancouver
Lopez-Gordo E, Chamberlain K, Riyad JM, Kohlbrenner E, Weber T. Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights. Viruses. 2024;16(3):442. doi:10.3390/v16030442
BibTeX
@article{LopezGordo2024,
author = {Lopez-Gordo, Estrella and Chamberlain, Kyle and Riyad, Jalish Mahmud and Kohlbrenner, Erik and Weber, Thomas},
title = {Natural Adeno-Associated Virus Serotypes and Engineered Adeno-Associated Virus Capsid Variants: Tropism Differences and Mechanistic Insights},
journal = {Viruses},
year = {2024},
volume = {16},
number = {3},
pages = {442},
doi = {10.3390/v16030442}
}
EUVIMED